McCourt Marion sold $984K of REGN
McCourt Marion (EVP Commercial) sold 1,132 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $869.43 ($0.98M total) on 2026-10-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may prompt short-term price adjustment, but the amount is modest relative to REGN's market cap.
Market read
Primary relevance is the insider sale; limited broader market effect.
What to watch
The 10b5-1 plan pre-arranged the sale, reducing informational value.
Background
Form 4 filings disclose insider transactions; a sale by a senior executive can be a data point for traders.
Ticker impact
SEC Form 4 shows EVP Commercial Marion McCourt sold 1,132 shares for $984K, reducing his stake to 10,871 shares.
likely pressure as the market prices in the insider sell
A C-level executive sold nearly $1M of stock under a 10b5-1 plan; such sales often signal limited confidence and can prompt short-term downside.
Market effects
Minimal impact on biotech sector; isolated insider transaction.
No broader regional effect.
Limited to REGN investors.
Counterpoint
The sale could be routine liquidity management, not a negative signal.
Key entities
- CompanyRegeneron Pharmaceuticals, Inc.
Biotech firm developing therapeutics.
- IndividualMarion McCourt
Executive Vice President, Commercial at Regeneron.



